External broker reports(aggregated public sources), Euroz Limited

Euroz Hartleys

A Western Australian diversified financial services company focused on providing financial services solutions to Institutional, Corporate & Private Clients. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Euroz Limited

Equity Bottom-Up

Botanix Pharmaceuticals / Equity Bottom-Up

<ul>
<li>BOT has successfully received confirmation from the FDA that the Sofpironium Bromide New Drug Application (NDA) is now formally under review.</li>
<li>This FDA communication initiates the formal review process, and follows BOT’s earlier September NDA submission.</li>
<li>The FDA confirmed there were no filing review issues identified and that the NDA was sufficiently complete to permit substantive review.</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


BOT has successfully received confirmation from the FDA that the Sofpironium Bromide New Drug Application (NDA) is now formally under review.
This FDA communication initiates the formal review process, and follows BOT’s earlier September NDA submission.
The FDA confirmed there were no filing review issues identified and that the NDA was sufficiently complete to permit substantive review.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Fda New Drug Application (Nda) Formally Under Review